[Modification of eicosanoid synthesis by calcium dobesilate].
Calcium dobesilate is a vasoactive drug with well-known effects on endothelial integrity, vascular wall permeability and blood viscosity. A clinical study demonstrated that serum thromboxane formation is significantly decreased by calcium dobesilate in patients suffering from peripheral vascular disease. Hence an in vitro study has been undertaken to determine the influence of calcium dobesilate on eicosanoid formation both by platelets and the arterial wall. Radio-thin-layer chromatography (RTLC) of human platelets does not show any influence of the drug on eicosanoid conversion in a dose range from 10 to 1000 micrograms/ml. By contrast, the vascular conversion of eicosanoids shows a dose-dependent trend towards a decrease in cyclooxygenase products. However, using the same doses, no effect is observed on vascular PGI2 formation in vitro, as assessed by means of the platelet aggregation bioassay and thus no inhibitory effect on cyclooxygenase of the arterial wall can be deduced. These laboratory findings provide no explanation for the clinical efficacy of calcium dobesilate and the diminution in serum thromboxane. A different mode of metabolic conversion of endogenous and exogenous arachidonic acid is suggested as explanation for these contradictory results.
D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism; D001557:Benzenesulfonates / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects; D002123:Calcium Dobesilate / Q000494:pharmacology*; D004537:Eicosanoic Acids / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000187:drug effects*; D011464:Epoprostenol / Q000378:metabolism; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects
D001095:Arachidonic Acids; D001557:Benzenesulfonates; D004537:Eicosanoic Acids; D016718:Arachidonic Acid; D002123:Calcium Dobesilate; D011464:Epoprostenol
Beeinflussung der Eicosanoidsynthese durch Kalzium-Dobesilat.